SCHEMBL6326657

SCHEMBL6326657

Nc1[nH]c(=O)c(C(=O)NCC2CCN(Cc3c(Cl)cccc3Cl)CC2)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR4 Q13639 6/20 0.49
CXCR4 P61073 1/20 0.47
DRD2 P14416 3/20 0.46
DRD4 P21917 3/20 0.46
DRD3 P35462 2/20 0.46
HDAC3 O15379 2/20 0.45
HDAC4 P56524 2/20 0.45
HDAC1 Q13547 2/20 0.45
HDAC7 Q8WUI4 2/20 0.45
HDAC2 Q92769 2/20 0.45
HDAC10 Q969S8 2/20 0.45
HDAC11 Q96DB2 2/20 0.45
HDAC8 Q9BY41 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HDAC9 Q9UKV0 2/20 0.45
HDAC5 Q9UQL6 2/20 0.45
ACHE P22303 1/20 0.44
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7254172 0.95 HTR4 (0.45) HTR4CXCR4DRD2DRD4DRD3
SCHEMBL6336897 0.92 HTR4 (0.50) HTR4DRD2DRD4DRD3HDAC3
SCHEMBL6329577 0.89 TP53 (0.54) HTR4CXCR4DRD2DRD4DRD3
SCHEMBL6329269 0.89 DRD2 (0.58) HTR4DRD2DRD4DRD3HDAC3
SCHEMBL6335662 0.88 HTR4 (0.50) HTR4DRD2DRD4DRD3HDAC3
SCHEMBL6329054 0.88 TP53 (0.57) HTR4CXCR4DRD2DRD4DRD3
SCHEMBL6329068 0.87 HTR4 (0.56) HTR4DRD2DRD4DRD3ACHE
SCHEMBL6328378 0.86 CXCR4 (0.52) HTR4CXCR4DRD2DRD4DRD3
SCHEMBL6328740 0.86 HDAC3 (0.50) HTR4DRD2DRD4DRD3HDAC3
SCHEMBL6329186 0.85 HTR4 (0.66) HTR4DRD2DRD4DRD3ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6979690-B2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC. (US) 2005-12-27 US claimed
US-20030207875-A1 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC 2003-11-06 US claimed
EP-1325921-A2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators Pfizer Inc. (US) 2003-07-09 EP claimed
US-6979690-B2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC. (US) 2005-12-27 US disclosed
US-20030207875-A1 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC 2003-11-06 US disclosed
WO-2003057688-A2 OXO OR OXY-PYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS PFIZER JAPAN INC. (JP) 2003-07-17 WO disclosed
EP-1325921-A2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators Pfizer Inc. (US) 2003-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207875-A1 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators HRH4, HRH2, HTR4 HTR4 3/4885CXCR4 249/4885DRD2 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.